Intercept Pharmaceuticals Performance

ICPTDelisted Stock  USD 19.00  0.00  0.00%   
The company retains a Market Volatility (i.e., Beta) of -6.79, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Intercept Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Intercept Pharmaceuticals is expected to outperform it. Intercept Pharmaceuticals right now retains a risk of 0.0%. Please check out Intercept Pharmaceuticals potential upside, as well as the relationship between the kurtosis and market facilitation index , to decide if Intercept Pharmaceuticals will be following its current trending patterns.

Risk-Adjusted Performance

0 of 100

 
Low
 
High
Very Weak
Over the last 90 days Intercept Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Intercept Pharmaceuticals is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Begin Period Cash Flow94.4 M
Total Cashflows From Investing Activities261.8 M
  

Intercept Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  1,900  in Intercept Pharmaceuticals on December 29, 2023 and sell it today you would earn a total of  0.00  from holding Intercept Pharmaceuticals or generate 0.0% return on investment over 90 days. Intercept Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Intercept, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  

Intercept Pharmaceuticals Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Intercept Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Intercept Pharmaceuticals, and traders can use it to determine the average amount a Intercept Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
ICPT
Based on monthly moving average Intercept Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Intercept Pharmaceuticals by adding Intercept Pharmaceuticals to a well-diversified portfolio.

Intercept Pharmaceuticals Fundamentals Growth

Intercept Stock prices reflect investors' perceptions of the future prospects and financial health of Intercept Pharmaceuticals, and Intercept Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Intercept Stock performance.

About Intercept Pharmaceuticals Performance

To evaluate Intercept Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Intercept Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Intercept Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Intercept Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Intercept's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company was incorporated in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 437 people.

Things to note about Intercept Pharmaceuticals performance evaluation

Checking the ongoing alerts about Intercept Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Intercept Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Intercept Pharmaceuticals is not yet fully synchronised with the market data
Intercept Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
Intercept Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported the previous year's revenue of 285.71 M. Net Loss for the year was (174.86 M) with profit before overhead, payroll, taxes, and interest of 284.73 M.
Intercept Pharmaceuticals currently holds about 404.78 M in cash with (26.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.58.
Over 81.0% of the company shares are owned by institutional investors
Evaluating Intercept Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Intercept Pharmaceuticals' stock performance include:
  • Analyzing Intercept Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Intercept Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
  • Examining Intercept Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Intercept Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Intercept Pharmaceuticals' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Intercept Pharmaceuticals' stock. These opinions can provide insight into Intercept Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Intercept Pharmaceuticals' stock performance is not an exact science, and many factors can impact Intercept Pharmaceuticals' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Consideration for investing in Intercept Stock

If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Share Portfolio
Track or share privately all of your investments from the convenience of any device